MK-3475 as Maintenance Therapy in Extensive Stage SCLC

Summary

This phase II trial studies how well pembrolizumab works in treating patients with extensive stage small cell lung cancer after completion of combination chemotherapy. Pembrolizumab may be effective in controlling small cell lung cancer for a longer period of time in patients with responsive or stable disease after completion of combination chemotherapy.

Timeline

Start

2015-02

Primary completion

2018-10

Completion

2018-10

Drugs

Indications